在癌症相关的脂肪组织萎缩过程中,2 型免疫得以维持。

IF 4.1 Q2 IMMUNOLOGY Immunotherapy advances Pub Date : 2021-06-02 eCollection Date: 2021-01-01 DOI:10.1093/immadv/ltab011
Patrick J Lenehan, Assunta Cirella, Amiko M Uchida, Stephanie J Crowley, Tatyana Sharova, Genevieve Boland, Michael Dougan, Stephanie K Dougan, Max Heckler
{"title":"在癌症相关的脂肪组织萎缩过程中,2 型免疫得以维持。","authors":"Patrick J Lenehan, Assunta Cirella, Amiko M Uchida, Stephanie J Crowley, Tatyana Sharova, Genevieve Boland, Michael Dougan, Stephanie K Dougan, Max Heckler","doi":"10.1093/immadv/ltab011","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Cachexia is a systemic metabolic disorder characterized by loss of fat and muscle mass, which disproportionately impacts patients with gastrointestinal malignancies such as pancreatic cancer. While the immunologic shifts contributing to the development of other adipose tissue (AT) pathologies such as obesity have been well described, the immune microenvironment has not been studied in the context of cachexia.</p><p><strong>Methods: </strong>We performed bulk RNA-sequencing, cytokine arrays, and flow cytometry to characterize the immune landscape of visceral AT (VAT) in the setting of pancreatic and colorectal cancers.</p><p><strong>Results: </strong>The cachexia inducing factor IL-6 is strongly elevated in the wasting VAT of cancer bearing mice, but the regulatory type 2 immune landscape which characterizes healthy VAT is maintained. Pathologic skewing toward Th1 and Th17 inflammation is absent. Similarly, the VAT of patients with colorectal cancer is characterized by a Th2 signature with abundant IL-33 and eotaxin-2, albeit also with high levels of IL-6.</p><p><strong>Conclusions: </strong>Wasting AT during the development of cachexia may not undergo drastic changes in immune composition like those seen in obese AT. Our approach provides a framework for future immunologic analyses of cancer associated cachexia.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":null,"pages":null},"PeriodicalIF":4.1000,"publicationDate":"2021-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/47/1e/ltab011.PMC8286632.pdf","citationCount":"0","resultStr":"{\"title\":\"Type 2 immunity is maintained during cancer-associated adipose tissue wasting.\",\"authors\":\"Patrick J Lenehan, Assunta Cirella, Amiko M Uchida, Stephanie J Crowley, Tatyana Sharova, Genevieve Boland, Michael Dougan, Stephanie K Dougan, Max Heckler\",\"doi\":\"10.1093/immadv/ltab011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Cachexia is a systemic metabolic disorder characterized by loss of fat and muscle mass, which disproportionately impacts patients with gastrointestinal malignancies such as pancreatic cancer. While the immunologic shifts contributing to the development of other adipose tissue (AT) pathologies such as obesity have been well described, the immune microenvironment has not been studied in the context of cachexia.</p><p><strong>Methods: </strong>We performed bulk RNA-sequencing, cytokine arrays, and flow cytometry to characterize the immune landscape of visceral AT (VAT) in the setting of pancreatic and colorectal cancers.</p><p><strong>Results: </strong>The cachexia inducing factor IL-6 is strongly elevated in the wasting VAT of cancer bearing mice, but the regulatory type 2 immune landscape which characterizes healthy VAT is maintained. Pathologic skewing toward Th1 and Th17 inflammation is absent. Similarly, the VAT of patients with colorectal cancer is characterized by a Th2 signature with abundant IL-33 and eotaxin-2, albeit also with high levels of IL-6.</p><p><strong>Conclusions: </strong>Wasting AT during the development of cachexia may not undergo drastic changes in immune composition like those seen in obese AT. Our approach provides a framework for future immunologic analyses of cancer associated cachexia.</p>\",\"PeriodicalId\":73353,\"journal\":{\"name\":\"Immunotherapy advances\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2021-06-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/47/1e/ltab011.PMC8286632.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunotherapy advances\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/immadv/ltab011\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy advances","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/immadv/ltab011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:恶病质是一种以脂肪和肌肉量减少为特征的全身性代谢紊乱,对胰腺癌等胃肠道恶性肿瘤患者的影响尤为严重。虽然导致肥胖等其他脂肪组织(AT)病变发生的免疫学变化已被充分描述,但尚未对恶病质背景下的免疫微环境进行研究:我们进行了大量 RNA 测序、细胞因子阵列和流式细胞术研究,以确定胰腺癌和结直肠癌患者内脏脂肪组织(VAT)的免疫环境特征:结果:诱导恶病质因子 IL-6 在癌症小鼠消瘦的 VAT 中强烈升高,但作为健康 VAT 特征的调节性 2 型免疫格局却得以保持。病理上没有向 Th1 和 Th17 炎症倾斜。同样,结直肠癌患者的增值血管也具有 Th2 特征,含有大量 IL-33 和 eotaxin-2,尽管 IL-6 水平也很高:结论:在恶病质发展过程中,消瘦的腹腔脂肪可能不会像肥胖的腹腔脂肪那样发生免疫组成的剧烈变化。我们的方法为今后对癌症相关恶病质进行免疫学分析提供了一个框架。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Type 2 immunity is maintained during cancer-associated adipose tissue wasting.

Objectives: Cachexia is a systemic metabolic disorder characterized by loss of fat and muscle mass, which disproportionately impacts patients with gastrointestinal malignancies such as pancreatic cancer. While the immunologic shifts contributing to the development of other adipose tissue (AT) pathologies such as obesity have been well described, the immune microenvironment has not been studied in the context of cachexia.

Methods: We performed bulk RNA-sequencing, cytokine arrays, and flow cytometry to characterize the immune landscape of visceral AT (VAT) in the setting of pancreatic and colorectal cancers.

Results: The cachexia inducing factor IL-6 is strongly elevated in the wasting VAT of cancer bearing mice, but the regulatory type 2 immune landscape which characterizes healthy VAT is maintained. Pathologic skewing toward Th1 and Th17 inflammation is absent. Similarly, the VAT of patients with colorectal cancer is characterized by a Th2 signature with abundant IL-33 and eotaxin-2, albeit also with high levels of IL-6.

Conclusions: Wasting AT during the development of cachexia may not undergo drastic changes in immune composition like those seen in obese AT. Our approach provides a framework for future immunologic analyses of cancer associated cachexia.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.00
自引率
0.00%
发文量
0
审稿时长
7 weeks
期刊最新文献
A rapid method to assess the in vivo multi-functionality of adoptively transferred engineered TCR T cells. Advancements in nuclear imaging using radiolabeled nanobody tracers to support cancer immunotherapy. Regulation of temporal cytokine production by co-stimulation receptors in TCR-T cells is lost in CAR-T cells. Tumour-Reactive Plasma Cells in Antitumour Immunity: Current Insights and Future Prospects Establishment of Humanised Xenograft Models as In Vivo Study for Lung Metastasis of Osteosarcoma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1